| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NADK |
| Uniprot No | O95544 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 64-446aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMSLHGPCPVTTFGPKACVLQNPQTIMHIQD PASQRLTWNK SPKSVLVIKKMRDASLLQPFKELCTHLMEENMIVYVEKKVLEDPAIASDE SFGAVKKKFC TFREDYDDISNQIDFIICLGGDGTLLYASSLFQGSVPPVMAFHLGSLGFL TPFSFENFQS QVTQVIEGNAAVVLRSRLKVRVVKELRGKKTAVHNGLGEKGSQAAGLDMD VGKQAMQYQV LNEVVIDRGPSSYLSN |
| 预测分子量 | 28 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于NADK(烟酰胺腺嘌呤二核苷酸激酶)重组蛋白研究的代表性文献，按研究主题分类整理：
1. **文献名称**：Production and characterization of recombinant human NAD kinase
**作者**：Kawai S, et al.
**摘要**：报道了在大肠杆菌中高效表达人源NADK重组蛋白的方法，通过亲和层析纯化获得高活性酶，并分析了其酶动力学特征及对NAD+底物的特异性。
2. **文献名称**：Crystal structure of NAD kinase from Mycobacterium tuberculosis
**作者**：Zheng R, et al.
**摘要**：解析了结核分枝杆菌NADK的晶体结构(2.1Å)，揭示了ATP结合域和底物识别机制，为设计针对该酶的抗菌药物提供了结构基础。
3. **文献名称**：NADK-mediated de novo NADP(H) synthesis is critical for prostate cancer progression
**作者**：Shi J, et al.
**摘要**：通过构建重组NADK蛋白探针，证明前列腺癌细胞中NADK过表达通过维持NADPH/GSH氧化还原稳态促进肿瘤生长，提示其作为治疗靶点的潜力。
注：以上为模拟文献案例，实际研究中建议通过PubMed(https://pubmed.ncbi.nlm.nih.gov)或Web of Science检索具体文献，检索时可使用关键词："NADK recombinant protein"、"NADK expression and purification" 或结合具体研究领域如 "NADK cancer"。近期研究多聚焦于其在代谢疾病和肿瘤中的功能机制解析。
**Background of NADK Recombinant Protein**
Nicotinamide adenine dinucleotide kinase (NADK) is a critical enzyme responsible for catalyzing the phosphorylation of NAD⁺ to generate NADP⁺, a coenzyme essential for reductive biosynthesis and cellular antioxidant defense. NADK regulates the balance between NAD⁺ and NADP⁺, influencing redox homeostasis, energy metabolism, and signaling pathways. Dysregulation of NADK activity has been linked to metabolic disorders, cancer, and neurodegenerative diseases, highlighting its physiological and therapeutic significance.
Recombinant NADK proteins are engineered using biotechnological platforms, such as *E. coli* or mammalian expression systems, to produce highly purified, functional enzymes for research and drug development. These proteins retain the catalytic activity of native NADK, enabling studies on enzyme kinetics, substrate specificity, and interaction with regulatory molecules. Recombinant NADK is widely used to investigate cellular NADPH metabolism, oxidative stress responses, and the role of NADP⁺-dependent pathways in disease models.
In structural biology, recombinant NADK facilitates crystallographic and cryo-EM studies to elucidate its mechanism and guide the design of inhibitors or activators. Additionally, it serves as a tool in high-throughput screening for compounds targeting NADPH-related disorders, such as diabetes or cancer. The development of recombinant NADK has advanced our understanding of NAD metabolism's complexity and its connections to health and disease, offering potential therapeutic strategies for conditions linked to metabolic imbalances.
×
